Ion337
Preclinical
Ionis PharmaceuticalsIon337 is one of 14 therapeutic programs targeting Dravet syndrome. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
16 competitors in Dravet Syndrome
#DrugCompanyPhaseTrials
1Sympazan
LundbeckPhase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Lorcaserin
EisaiPhase 3
Soticlestat
TakedaPhase 3
Translarna
PPTC Therapeutics
Phase 2
Calan
VVal Adams
Phase 2
GWP42003-P
Jazz PharmaceuticalsPhase 2
Clemizole Hcl
EEpygenix
Phase 3
LP352
LLongboard Pharmaceuticals
Phase 3
Zorevunersen
SStoke Therapeutics, Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ion337. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company